Get the Stockscreener App
8.96
3.31%
0.29
Amneal Pharmaceuticals Inc stock is traded at $8.96, with a volume of 1.36M.
It is up +3.31% in the last 24 hours and up +9.50% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$8.67
Open:
$8.69
24h Volume:
1.36M
Relative Volume:
1.13
Market Cap:
$2.74B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-13.17
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+7.91%
1M Performance:
+9.50%
6M Performance:
+5.50%
1Y Performance:
+63.74%
1-Day Range:
$8.68
$9.16
1-Week Range:
$7.61
$9.16
52-Week Range:
$5.18
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
8.96 | 2.74B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
168.92 | 75.15B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.62 | 47.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.97 | 47.70B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.21 | 18.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.29 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal projects $3B-$3.1B revenue in 2025 with biosimilars and CREXONT as key drivers - MSN
Amneal Pharmaceuticals’ Earnings Call Highlights Robust Growth - MSN
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Weight Loss Drug Stock to Buy According to Analysts? - Insider Monkey
Amneal Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Amneal Pharmaceuticals Inc (AMRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Amneal Pharmaceuticals Reports Strong 2024 Financial Results - TipRanks
10 Best Weight Loss Drug Stocks to Buy According to Analysts - Insider Monkey
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Phocas Financial Corp. - MarketBeat
Earnings call transcript: Amneal Pharmaceuticals Q4 2024 misses EPS forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Amneal Pharmaceuticals Q4 2024 misses EPS forecast - Investing.com UK
Amneal Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars - Benzinga
Amneal: Q4 Earnings Snapshot - Thehour.com
Vertigo Drugs Market Projected To Witness Massive Growth, - openPR
Amneal Pharma rises on strong 2025 revenue forecast, Q4 revenue beat - TradingView
Amneal Pharmaceuticals (AMRX) Q4 Earnings Lag Estimates - Yahoo Finance
Amneal Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks
Amneal’s (NASDAQ:AMRX) Q4 Sales Beat Estimates, Guides for Strong Full-Year Sales - Yahoo Finance
Amneal Pharmaceuticals stock rises over 2% on revenue beat, strong guidance - Investing.com India
(AMRX) Amneal Pharmaceuticals Sees Fiscal Year 2025 Adjusted EPS Range $0.65$0.70 - Marketscreener.com
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results - The Bakersfield Californian
Can Amneal's 17% Revenue Growth Overcome Ongoing Losses? Q4 Earnings Reveal Key Strategy - StockTitan
Earnings Scheduled For February 28, 2025 - Benzinga
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow By Stock Story - Investing.com Canada
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow - The Globe and Mail
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Low Price Pharma Stock to Invest In Right Now? - Insider Monkey
Amneal Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock? - MSN
Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q4 Earnings - MSN
AMNEAL PHARMACEUTICALS Earnings Preview: Recent $AMRX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Amneal stock climbs 10% amid J.P. Morgan upgrade - MSN
Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock - AOL
Sector Update: Health Care -February 24, 2025 at 03:33 pm EST - Marketscreener.com
Amneal stock climbs 10% amid J.P. Morgan upgrade (AMRX:NASDAQ) - Seeking Alpha
JPM lifts Amneal Pharmaceuticals stock rating to overweight on strong execution - Investing.com
Why Amneal Pharmaceuticals Stock is Gaining Attention - TipRanks
JPMorgan Upgrades Amneal Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $12 From $9 - Marketscreener.com
Amneal Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan - TipRanks
Robust Growth and Strategic Positioning Drive Buy Rating for Amneal Pharmaceuticals - TipRanks
JPMorgan raises Amneal stock to overweight, target to $12 By Investing.com - Investing.com Canada
JP Morgan Upgrades Amneal Pharmaceuticals (AMRX) - MSN
JPMorgan raises Amneal stock to overweight, target to $12 - Investing.com
Amneal pharma, Aramark, Bluebird Bio - TradingView
Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth - MSN
Amneal gains FDA approval for dementia and oncology drugs - MSN
Amneal Launches Mesalamine and Receives FDA Approval for Lenalidomide - Pharmacy Practice News
AMRXAmneal Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Amneal Launches Mesalamine And Receives U.S. FDA Approval For Lenalidomide - Marketscreener.com
Amneal Pharmaceuticals Launching Mesalamine, Gets US FDA Approval for Lenalidomide - Marketscreener.com
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):